Ameriprise
BLRX

Ameriprise’s BioLineRX BLRX Stock Holding History

Ameriprise’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-18
Closed -$9K – 3726
2018
Q2 		$9K Buy
+18
New +$9.56K ﹤0.01% 3626
2014
Q4 		– Hold
0
– – – 3757
2014
Q3 		– Sell
-1
Closed -$1.07K – 5810
2014
Q2 		$1K Buy
+1
New +$1.25K ﹤0.01% 5329
2014
Q1 		– Hold
0
– – – 5319
2013
Q4 		– Hold
0
– – – 5162
2013
Q3 		– Hold
0
– – – 5606
2013
Q2 		– Hold
0
– – – 5540

Other funds holding BLRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

Ameriprise's BLRX Position: Q3 2018 in Review

Ameriprise sold out of BioLineRX (BLRX) in Q3 2018, closing a stake of 18 shares — an estimated $9K sold.

Ameriprise first reported a position in BLRX in Q2 2014 and held it in 2 quarters. The position peaked at $9K in Q2 2018. 26 funds tracked by Wall St. Rank hold BLRX as of Q3 2018.

  • Ameriprise reported no remaining BioLineRX position as of Q3 2018 after selling out during the quarter.
  • Ameriprise sold 18 BioLineRX shares in Q3 2018, an estimated $9K.
  • Ameriprise first reported a position in BioLineRX in Q2 2014 and held it in 2 quarters.
  • Ameriprise's BioLineRX position peaked at $9K in Q2 2018.
  • 26 funds tracked by Wall St. Rank held BioLineRX as of Q3 2018.

Based on Ameriprise's 13F filing for Q3 2018, filed 14 Nov 2018.